Company intelligence / Profile preview

Stoke Therapeutics

Bedford, Massachusetts, United Statesinvestor.stoketherapeutics.com ↗

Ownership: Public · STOK
Employees: ~125
Development stage: Phase 3

Overview

Stoke’s lead asset zorevunersen (STK‑001) has shown substantial and sustained reductions in convulsive seizures in Dravet syndrome patients over two years of treatment. Improvements in cognition and behavior have also been observed within nine months. The pivotal global Phase 3 EMPEROR study for zorevunersen will initiate in Q2 2025 with data expected in H2 2027. The company’s second program STK‑002 for ADOA is entering clinical studies. Additional programs are advancing preclinically or through early partnerships.

Therapeutic areas: OphthalmologyNeurology
Modalities: Antisense oligonucleotides (ASOs)RNA-based medicines
Industry: Biotech

Drug pipeline

3 assets

zorevunersen

2 more assets in the full pipeline.

Request access →

Partnerships

Biogen Inc.: Global collaboration for zorevunersen—Biogen holds ex-North America rights; Stoke retains US/Canada/Mexico rights.Acadia Pharmaceuticals partnership on certain neurodevelopmental disorders including Rett syndrome.

Financials

Market cap: $1.9B
Total revenue: $9.3M
Enterprise value: $1.6B

Beyond the preview

Go deeper on Stoke Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stoke Therapeutics.

Explore the full profile